Yeah, so the new vaccine trial that we had data last week from, it’s very impressive. I think it’s on par with what we achieved with neoadjuvant treatments. And the question, what will the role be? It’s a little bit unclear. It was designed in another era where we had a lot of adjuvant treatments, a lot adjuvating immunotherapies, and the control arm in that trial was pembrolizumab...
Yeah, so the new vaccine trial that we had data last week from, it’s very impressive. I think it’s on par with what we achieved with neoadjuvant treatments. And the question, what will the role be? It’s a little bit unclear. It was designed in another era where we had a lot of adjuvant treatments, a lot adjuvating immunotherapies, and the control arm in that trial was pembrolizumab. I think, honestly, it’s not supported by data, but what I think where it would definitely probably start having its role is in patients failing neoadjuvant treatment. Only half of the patients actually have a complete response of patients with a complete response. Could that be a way to salvage those patients not having a complete response by utilising these new mRNA vaccines? I think that’s a very interesting concept linking what we have learned in the recent years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.